Although no study to date has explored the function of VCAM1 in NPM1-mutated AML patients, we speculated that the downregulation of VCAM1 may reduce the stroma-mediated protection of leukemic cells, which might confer favorable outcomes to AML patients with NPM1 mutations. This evidence concerns the gene VCAM1 and acute myeloid leukemia.